|
GCIG CLINICAL TRIALS
GCIG Concept/Trial Registration Form
AGO-OVAR - Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe
Ovarialkarzinom Germany
Title - Evaluation of Predictive Factors for Complete Resection in
Platinum-Sensitive Recurrent Ovarian Cancer
Protocol Number - AGO-OVAR OP.2 (DESKTOP II)
Status – open to accrual
Participating Groups – MITO, AGO-Austria
Contact Information – Philipp Harter, M.D; Dr. Horst Schmidt Kliniken
GmbH, Department of Gynecology and Gynecologic Oncology,
Ludwig-Erhard-Str. 100, 65199 Wiesbaden, Germany; P: +49 611 43 32 03; F:
+49 611 43 32 05;
E: office-wiesbaden@ago-ovar.de
Title - Comparing Treatment with Carboplatin to Paclitaxel plus Carboplatin
in a Relapse Therapy
Protocol Number - AGO-OVAR-2-2
Status - completed
Participating Groups - AGO Ovarian Cancer Study Group, MRC/NCRI
Collaboration with ICON-4
Contact Information - Andreas Du Bois, M.D. Ph.D.;
Dr.-Horst-Schmidt-Kliniken GmbH, Department of Gynecology and Gynecologic
Oncology, Ludwig-Erhard-Str. 100, 65199 Wiesbaden, Germany;
P: +49 611 43 32 03; F: +49 611 43 32 05;
E: dubois.hsk-wiesbaden@uumail.de
Title - A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma who Failed First-Line Platinum-Based Therapy
Protocol Number - AGO-OVAR-2.5, NCIC-OV15, EORTC-55005
Status - completed
Participating Groups - AGO Ovarian Cancer Study Group, NCIC-CTG, EORTC
Contact Information - Jacobus Pfisterer, M.D. Ph.D.; University of
Mannheim, Department of Gynecology, Theodor-Kutzer-Ufer 1-3, 68167
Mannheim, Germany; P: +49 621 418 71 39; F: +49 621 418 73 21;
E: office-mannheim@ago-ovar.de
Title - A Randomized Phase III Trial Comparing Second-Line Carboplatin
Chemotherapy with Epoetin versus Carboplatin Alone in Platinum-Sensitive
Recurrences in Ovarian Cancer Patients
Protocol Number - AGO-OVAR-2-7
Status - terminated
Participating Groups - AGO Ovarian Cancer Study Group, GINECO/GERCOR
Contact Information - Christian Jackisch, M.D.
Title - A Randomized Phase III Study Comparing First-Line Chemotherapy with
Gemcitabine, Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin
in Previously Untreated Patients with Epithelial Ovarian Cancer FIGO stages
I-IV
Protocol Number - AGO-OVAR-9
Status - no longer recruiting
Participating Groups - AGO Ovarian Cancer Study Group, GINECO/GERCOR, NSGO
Contact Information - Andreas Du Bois, M.D. Ph.D.; Dr. Horst Schmidt Klinik
GmbH, Department of Gynecology and Gynecologic Oncology, Ludwig-Erhard-Str.
100, 65199 Wiesbaden, Germany;
P: +49 611 43 32 03; F: +49 611 43 32 05; E:
dubois.hsk-wiesbaden@uumail.de
EORTC - European Organization for Research and Treatment of Cancer
Title - A Randomised Trial in Relapsed Ovarian Cancer: Early Treatment Based on CA 125 Levels Alone versus Delayed Treatment Based on Conventional Clinical Indicators
Protocol Number - EORTC-55955, MRC-OV05
Status - Active
Participating Groups - EORTC, Medical Research Council/National Cancer Research Institute
Contact Information - lgi@eortc.be
Title - A Randomised Phase III Study for the Treatment of Recurrent Epithelial Ovarian Cancer: Chemotherapy Alone versus Chemotherapy Followed by Secondary Cytoreductive Surgery in Patients with a Treatment-Free Interval of more than 12 Months
Protocol Number - EORTC-55963
Status - Active
Participating Groups - EORTC
Contact Information - lgi@eortc.be
Title - A Phase III Study of Cisplatin plus Topotecan Followed by Paclitaxel plus Carboplatin versus Paclitaxel plus Carboplatin as First Line Chemotherapy in Women with Newly Diagnosed Advanced Epithelial Ovarian Cancer
Protocol Number - NCIC-OV16/EORTC-55012/GEICO-0101
Status - Active
Participating Groups - NCIC, EORTC, GEICO
Contact Information - lgi@eortc.be
Title - Randomised Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery versus Concomitant Radiotherapy and Chemotherapy in FIGO stage IB2, IIA>4 cm or IIB Cervical Cancer
Protocol Number - EORTC-55994
Status - Active
Participating Groups - EORTC
Contact Information - lgi@eortc.be
Title - A Randomised Trial of Adjuvant Treatment with Radiation plus Chemotherapy versus Radiation Alone in High Risk Endometrial Carcinoma
Protocol Number - EORTC-55991
Status - Active
Participating Groups - EORTC
Contact Information - lgi@eortc.be
Title - A Randomized Trial of Adriamycin (A), Cisplatin (P) versus Paclitaxel (T), and Adriamycin (A) and Cisplatin (P) in Patients with Relapsed or Locally Advanced Inoperable Endometrial Cancer
Protocol Number - EORTC-55984
Status - Active
Participating Groups - EORTC
Contact Information - nick.reed.wg@northglasgow.scot.nhs.uk, m.bolis@iol.it
Title - Phase II Clinical Trial on Taxol as a Single Agent in Locally Advanced and/or Metastatic or Recurrent Vulva Cancer not Amenable for Surgery and/or Radiotherapy
Protocol Number - EORTC-55985
Status - Active
Participating Groups - EORTC
Contact Information - lgi@eortc.be
GOG - Gynecologic Oncology Group
Title - A Phase II Evaluation of Docetaxel(NSC #628503) and Gemcitabine(NSC #613327) Plus G-CSF in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus
Protocol Number - GOG-0087
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase II Evaluation of Epothilone-B BMS 247550 (IND #59,699 NSC #710428) in the Treatment of Recurrent or Persistent Platinum and Paclitaxel Refractory Ovarian or Primary Peritoneal Cancer
Protocol Number - GOG-0126
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase II Evaluation of Triapine (NCI-Supplied Agent: NSC #663249, IND #68338)in Combination with Cisplatin (Commercially Available: NSC #119875) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma
Protocol Number - GOG-0126
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase II Evaluation of Pemetrexed (Alimta, LY231514, IND #40061) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma
Protocol Number - GOG-0126
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase II Evaluation of Weekly Topotecan Hydrochloride (Hycamtin NSC #609699) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix
Protocol Number - GOG-0127
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase II Evaluation of Pemetrexed (Alimta, LY231514, IND #40061) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Protocol Number - GOG-0129
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC #628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Protocol Number - GOG-0130
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - Acquisition of Human Gynecologic Specimens and Serum to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer
Protocol Number - GOG-0136
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase II Evaluation of Irofulven (IND #55804, NSC #683863) in the Treatment of Recurrent or Persistent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
Protocol Number - GOG-0146
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Randomized Phase II Evaluation of Topotecan (NSC #609699) Administered Daily X 5 Every 3 Weeks VS. Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Protocol Number - GOG-0146
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - Intraoperative Lymphatic Mapping and Sentinel Node (SN) Identification in Patients with Squamous Cell Carcinoma of the Vulva
Protocol Number - GOG-0173
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus "Pulsed" Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia
Protocol Number - GOG-0174
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Randomized Phase III Trial of IV Carboplatin(AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin(AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x3 Courses Plus Observation in Patients with Early Stage Ovarian Carcinoma
Protocol Number - GOG-0175
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase II Evaluation of Trastuzumab (NSC #688097(MoAb HER2)) in Patients with Advanced, Recurrent or Persistent Endometrial Carcinoma with or without Prior Chemotherapy
Protocol Number - GOG-0181
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - Phase II Study of Paclitaxel for Ovarian Stromal Tumors as First-Line or Second-Line Therapy
Protocol Number - GOG-0187
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - Phase II Study of Faslodex (IND #52,121) in Recurrent/Metastatic Endometrial Carcinoma
Protocol Number - GOG-0188
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - An Exploratory Evaluation of Fenretinide (4-HPR)(IND #39,812) as a Chemopreventive Agent for Ovarian Carcinoma
Protocol Number - GOG-0190
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Randomized Phase III Trial of Amifostine vs No Treatment for Platinum Induced Peripheral Neuropathy
Protocol Number - GOG-0192
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Randomized Study of Tamoxifen versus Thalidomide in Patients with Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma after First Line Chemotherapy
Protocol Number - GOG-0198
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - Prospective Study of Risk-Reducing Salpingo-Oophorectomy and Longitudinal CA-125 Screening among Women at Increased Genetic Risk of Ovarian Cancer
Protocol Number - GOG-0199
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Randomized Phase III Trial of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix
Protocol Number - GOG-0204
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva
Protocol Number - GOG-0205
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - Lymphatic Mapping and Sentinel Node Identification in Patients with Stage IB1 Cervical Carcinoma
Protocol Number - GOG-0206
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Randomized Double-Blind Phase II Trial of Celecoxib, a Cox 2 Inhibitor, in the Treatment of Patients with Cervical Intraperitoneal Neoplasia 3 (CIN3)
Protocol Number - GOG-0207
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer
Protocol Number - GOG-0209
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Molecular Staging Study of Endometrial Carcinoma
Protocol Number - GOG-0210
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase II Pilot Investigation of the Relationship of Short Term Depo-Provera (Medroxprogesterone Acetate)(NSC#27408) Exposure to the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
Protocol Number - GOG-0211
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax(TM)(CT-2103)(IND# 61013), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
Protocol Number - GOG-0212
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase II Randomized Study of the Effect of Zoledronic Acid Versus Observation on Bone Mineral Density of the Lumbar Spine in Women who Elect to Undergo Risk Reducing Surgery that Results in Removal of Both Ovaries
Protocol Number - GOG-0215
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase II Trial of Pemetrexed (Alimta,LY231514,IND #40061) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor
Protocol Number - GOG-0217
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (Rhumab Vegf, NSC #704865, IND #7921) Followed by Placebo, versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Peritoneal Primary Cancer
Protocol Number - GOG-0218
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase III Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2,IIA.IIB,IIIB and IVA Cervical Carcinoma Limited to the Pelvis
Protocol Number - GOG-0219
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - Pelvic Mass Study to Develop Serum Proteomic Profiles (Signatures) for Epithelial Ovarian Cancer Diagnosis and Prognosis
Protocol Number - GOG-0220
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - Prospective Evaluation of Pelvic Exenteration in Patients with Recurrent Cervical Cancer
Protocol Number - GOG-0222
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase II Evaluation of Bevacizumab (rhuMAb VEGF)(NSC# 704865, IND #7921) in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix (Group A)
Protocol Number - GOG-0227
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase II Evaluation of Bevacizumab (NCI-Supplied Agent: NSC #704865, IND #7921) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Protocol Number - GOG-0229
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase II Evaluation of Thalidomide (NSC #66847, IND #48832) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus
Protocol Number - GOG-0230
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - Validation of Tumor-Infiltrating T-Cells as a Biomarker for Advanced Epithelial Ovarian Cancer
Protocol Number - GOG-8005
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase I Study of Extended Field Radiation Therapy with Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients with Cervical Carcinoma Metastatic to the Para-Aortic Lymph Nodes
Protocol Number - GOG-9804
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - Phase I Toxicity Trial of Doxorubicin-Cisplatin Followed by Whole Abdominal Irradiation for Advanced Endometrial Carcinoma
Protocol Number - GOG-9908
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase I Study of Whole Pelvic Radiation Therapy with Concomitant Cisplatin and Gemcitabine Chemotherapy in Patients with Cervical Carcinoma (Stages I-IV) Limited to the Pelvis
Protocol Number - GOG-9912
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase I Study Using Low Dose Abdominal Radiotherapy as a Docetaxel Chemosensitizer for Recurrent, Persistent or Advanced Ovarian, Peritoneal or Fallopian Tube Cancer
Protocol Number - GOG-9915
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase I Trial of Intravenous Paclitaxel Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel in Patients with Previously Untreated Epithelial Ovarian Carcinoma, Fallopian Tube or Primary Peritoneal Carcinoma
Protocol Number - GOG-9916
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Dose-Escalating Phase I Study with an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC #214240) and Intravenous Paclitaxel (NSC #673089) in Patients with Previously Untreated Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma
Protocol Number - GOG-9917
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
Title - A Phase I Trial of Tailored Radiation Therapy with Concomitant Cetuximab (C225, NSC #714692) and Cisplatin (NSC #119875) in the Treatment of Patients with Cervical Cancer
Protocol Number - GOG-9918
Status - active
Lead Group - Gynecologic Oncology Group
Contact Information - gcigquery@gogstats.org
MITO - Multicenter Italian Trials in Ovarian Cancer
Title - Carboplatin + Paclitaxel vs. Carboplatin + Stealth Liposomal
Doxorubicin in Patients with Ovarian Cancer. A Randomised Multicentre Trial. Protocol Number - MITO-2 Status - open to accrual Participating Groups - National Cancer Institute of Naples (seeking partners) Contact Information - Sandro Pignata; P: 00390815903637; E:
sandro.pignata@fondazionepascale.it
Title - Randomised Phase III Study of Gemcitabine vs. Pegylated Liposomal
Doxorubicin in Progressive/Recurrent Ovarian Cancer. The MITO-3 Study. Protocol Number - MITO-3 Status - open to accrual Participating Groups - University of Rome (seeking partners) Contact Information - Giovanni Scambia; P: 0039063052132; E:
ginecol1@rm.unicatt.it
MRC/NCRI - Medical Research Council/National Cancer Research Institute
Title - An International, Five-Arm, Randomised Trial of Carboplatin and Paclitaxel versus Triplet or Sequential Doublet Combinations in Patients with Epithelial Ovarian or Primary Peritoneal Carcinoma
Protocol Number - ICON5/GOG182, ISRCTN 41636183
Status - Active
Participating Groups - ICON, GOG
Contact Information - peter.harper@kcl.ac.uk, hpearce@ctu.mrc.ac.uk
Title - A Randomised Trial in Relapsed Ovarian Cancer: Early Treatment Based on CA125 Levels Alone versus Delayed Treatment Based on Conventional Clinical Indicators
Protocol Number - OV05/EORTC 55955, ISRCTN 87786644
Status - Active
Participating Groups - EORTC
Contact Information - Gordon.Rustin@whht.nhs.uk, ca@ctu.mrc.ac.uk
Title - ASTEC: A Randomised Trial of Lymphadenectomy and of External Beam Radiotherapy in the Treatment of Endometrial Cancer
Protocol Number - ISRCTN 16571884
Status - Active
Participating Groups - MRC/NCRI, NCIC EN.5 (radiotherapy randomisation only)
Contact Information - hkitchener@central.cmht.nwest.nhs.uk, Peter.Blake@rmh.nthames.nhs.uk, ca@ctu.mrc.ac.uk
NCIC CTG - National Cancer Institute of Canada Clinical Trials Group
Note: NCIC CTG lead groups are italicized; NCIC CTG participating groups are regular type
Title - Randomized Phase III Study Comparing Upfront Debulking Surgery versus Neoadjuvant Chemotherapy in Patients with Stage IIIC or IV Epithelial Ovarian Carcinoma
Protocol Number - NCIC OV.13, EORTC 55971
Status - Active
Participating Groups - NCIC CTG, EORTC GCG
Contact Information - lgi@eortc.be
Title - A Phase III Study of Cisplatin plus Topotecan Followed by Paclitaxel versus Paclitaxel plus Carboplatin as First-line Chemotherapy in Women with Newly Diagnosed Advanced Epithelial Ovarian Cancer
Protocol Number - NCIC CTG OV.16, EORTC 55012,GEICO 0101
Status - Active
Participating Groups - NCIC CTG, EORTC GCG, GEICO
Contact Information - mbacon@ctg.queensu.ca
Title - Phase II Study of OSI-774 (NSC 718781) Given in Combination with Carboplatin in Patients with Recurrent Epithelial Ovarian Cancer
Protocol Number - NCIC CTG IND.149
Status - Active
Participating Groups - NCIC CTG
Contact Information - eeisenhauer@ctg.queensu.ca
Title - A Phase III Randomized Trial to Evaluate the Effect of Raising Hemoglobin Using Erythropoetin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer
Protocol Number - NCIC CTG CX 4, GOG #165
Status - Active
Participating Groups - NCIC CTG, GOG
Contact Information - c/o GOG
Title - Phase III Randomized Trial Comparing TAH BSO versus TAH BSO plus Adjuvant Pelvic Irradiation in Stage I (Intermediate Risk) Carcinoma of the Endometrium
Protocol Number - NCIC CTG EN.5
Status - Active
Participating Groups - NCIC CTG (data to be combined with MRC ASTEC trial)
Contact Information - mbacon@ctg.queensu.ca
Title - Phase II Study of OSI-774 (NSC 718781) in Patients with Locally Advanced and/or Metastatic Carcinoma of the Endometrium
Protocol Number - NCIC CTG IND.148
Status - Active
Participating Groups - NCIC CTG
Contact Information - eeisenhauer@ctg.queensu.ca
Title - Randomized Phase III Trial of Weekly Parenteral Methotrexate versus "Pulsed" Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia
Protocol Number - NCIC CTG GT.1, GOG 174
Status - Active
Participating Groups - NCIC CTG, GOG
Contact Information - c/o GOG
SGCTG - Scottish Gynaecological Cancer Trials Group
Current Clinical Trials of the Scottish Gynaecological Cancer Trials Group
|
